Adult: As an adjunctive therapy: 4-12 g daily in divided doses for 5-7 days. For chronic hepatic insufficiency, 4 g daily over an indefinite period. Child: As an adjunctive therapy: 50-100 mg/kg daily in divided doses for 5-7 days.
Oral Preoperative intestinal antisepsis
Adult: 1 g hrly for 4 hr then 4 hrly for 2-3 days before surgery. Child: 6-12 yr 250-500 mg 4 hrly for 2-3 days before surgery; >12 yr 1 g 4 hrly for 2-3 days before surgery.
Topical/Cutaneous Skin infections
Adult: As cream/oint: Clean the affected area and apply bid. Child: >2 yr Same as adult dose.
Dosage adjustment needed.
May be taken with or without food.
Hypersensitivity to neomycin and other aminoglycosides. Intestinal obstruction. Infants <1 yr.
Patient w/ neuromuscular disorders (e.g. myasthenia gravis), pre-existing vertigo, tinnitus or hearing loss. Prolonged use may result in overgrowth of non-susceptible organisms. Renal and hepatic impairment. Childn. Pregnancy and lactation.
Symptoms: Exacerbation of adverse events (e.g. nausea, diarrhoea, nephrotoxicity, ototoxicity). Management: Prolonged assisted ventilation. Haemodialysis is indicated if renal and auditory impairment occur.
Additive nephrotoxic and neurotoxic effect w/ other aminoglycosides (e.g. paromomycin), bacitracin, cisplatin, vancomycin, amphotericin B, polymyxin B, colistin and viomycin. Enhanced toxicity w/ potent diuretics (e.g. ethacrynic acid, furosemide). May impair the absorption of other drugs (e.g. phenoxymethylpenicillin, digoxin, methotrexate and some vit). May reduce the efficacy of OCs. May enhance the effect of acarbose. May enhance the effect of non-depolarising muscle relaxants. May antagonise the parasympathomimetic effect of neostigmine and pyridostigmine. May increase the risk of hypocalcaemia in patients receiving bisphosphonates. May alter INR when given w/ anticoagulants. May inactivate oral typhoid vaccine.
Description: Neomycin interferes w/ bacterial protein synthesis by binding to 30S ribosomal subunits. Pharmacokinetics: Absorption: Poorly absorbed from the GI tract. Time to peak plasma concentration: 1-4 hr (oral). Distribution: Low concentrations in intestinal wall and muscles. Volume of distribution: 0.36 L/kg. Plasma protein binding: ≤30%. Metabolism: Undergoes minimal hepatic metabolism. Excretion: Via faeces (approx 97% of an oral dose, as unchanged drug); via urine (30-50% of absorbed drug, unchanged). Plasma half-life: 2-3 hr.
Anon. Neomycin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 24/10/2014.Baclezene Cream (Curazene, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 24/10/2014.Buckingham R (ed). Neomycin. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 24/10/2014.McEvoy GK, Snow EK, Miller J et al (eds). Neomycin Sulfate (Topical). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 24/10/2014.McEvoy GK, Snow EK, Miller J et al (eds). Neomycin Sulfate. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 24/10/2014.